Thursday, Aug. 07, 2008 IMPAX Reports Positive Results in Phase III Trial with IPX056 -Provides Update on Brand Pharmaceutical Program- -Company Presenting Today at the Bank of America Specialty Pharmaceutical Conference-
HAYWARD, Calif. — IMPAX Laboratories, Inc. today announced that IPX056, an investigational extended-release formulation of baclofen, has met its clinical endpoints in a Phase III study of spasticity in multiple sclerosis patients. The Company also is providing an update on its brand pharmaceutical product program, which resides in its IMPAX Pharmaceuticals Division.
In a 173-patient, placebo and active comparator-controlled double blind Phase III study with a seven-week open label follow on, IPX056 was shown to be effective versus placebo in reducing spasticity in multiple sclerosis patients. IPX056 is an extended-release formulation of baclofen, the drug of choice in the treatment of spasticity, which has the potential to offer improved control of symptoms and dosing convenience.
Thursday, Aug. 07, 2008
IMPAX Reports Positive Results in Phase III Trial with IPX056
-Provides Update on Brand Pharmaceutical Program- -Company Presenting Today at the Bank of America Specialty Pharmaceutical Conference-
HAYWARD, Calif. — IMPAX Laboratories, Inc. today announced that IPX056, an investigational extended-release formulation of baclofen, has met its clinical endpoints in a Phase III study of spasticity in multiple sclerosis patients. The Company also is providing an update on its brand pharmaceutical product program, which resides in its IMPAX Pharmaceuticals Division.
In a 173-patient, placebo and active comparator-controlled double blind Phase III study with a seven-week open label follow on, IPX056 was shown to be effective versus placebo in reducing spasticity in multiple sclerosis patients. IPX056 is an extended-release formulation of baclofen, the drug of choice in the treatment of spasticity, which has the potential to offer improved control of symptoms and dosing convenience.
» Read More
If you want to leave a comment to this article, you need to return-to (or remain on) - this page
============================================